Works by Mateos, Maria ‐ Victoria


Results: 224
    1
    2

    Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible.

    Published in:
    EJHaem, 2020, v. 1, n. 2, p. 481, doi. 10.1002/jha2.77
    By:
    • Sonneveld, Pieter;
    • Mateos, María‐Victoria;
    • Alegre, Adrian;
    • Facon, Thierry;
    • Hulin, Cyrille;
    • Hashim, Mahmoud;
    • Vincken, Talitha;
    • Kampfenkel, Tobias;
    • Cote, Sarah;
    • He, Jianming;
    • Lam, Annette;
    • Moreau, Philippe
    Publication type:
    Article
    3

    The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.

    Published in:
    Oncologist, 2016, v. 21, n. 3, p. 333, doi. 10.1634/theoncologist.2015-0303
    By:
    • Caers, Jo;
    • Fernández de Larrea, Carlos;
    • Leleu, Xavier;
    • Heusschen, Roy;
    • Zojer, Niklas;
    • Decaux, Olivier;
    • Kastritis, Efstathios;
    • Minnema, Monique;
    • Jurczyszyn, Artur;
    • Beguin, Yves;
    • Wäsch, Ralph;
    • Palumbo, Antonio;
    • Dimopoulos, Meletios;
    • Mateos, Maria Victoria;
    • Ludwig, Heinz;
    • Engelhardt, Monika
    Publication type:
    Article
    4

    Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial.

    Published in:
    Emerging Microbes & Infections, 2022, v. 11, n. 1, p. 1833, doi. 10.1080/22221751.2022.2098059
    By:
    • Sánchez Barrueco, Álvaro;
    • Mateos-Moreno, María Victoria;
    • Martínez-Beneyto, Yolanda;
    • García-Vázquez, Elisa;
    • Campos González, Alfonso;
    • Zapardiel Ferrero, Javier;
    • Bogoya Castaño, Abel;
    • Alcalá Rueda, Ignacio;
    • Villacampa Aubá, José Miguel;
    • Cenjor Español, Carlos;
    • Moreno-Parrado, Laura;
    • Ausina-Márquez, Verónica;
    • García-Esteban, Sandra;
    • Artacho, Alejandro;
    • López-Labrador, F. Xavier;
    • Mira, Alex;
    • Ferrer, María D.
    Publication type:
    Article
    5

    Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.

    Published in:
    European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x
    By:
    • Delforge, Michel;
    • Terpos, Evangelos;
    • Richardson, Paul G.;
    • Shpilberg, Ofer;
    • Khuageva, Nuriet K.;
    • Schlag, Rudolf;
    • Dimopoulos, Meletios A.;
    • Kropff, Martin;
    • Spicka, Ivan;
    • Petrucci, Maria T.;
    • Samoilova, Olga S.;
    • Mateos, Maria-Victoria;
    • Magen-Nativ, Hila;
    • Goldschmidt, Hartmut;
    • Esseltine, Dixie-Lee;
    • Ricci, Deborah S.;
    • Liu, Kevin;
    • Deraedt, William;
    • Cakana, Andrew;
    • van de Velde, Helgi
    Publication type:
    Article
    6

    Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

    Published in:
    European Journal of Haematology, 2011, v. 86, n. 1, p. 23, doi. 10.1111/j.1600-0609.2010.01533.x
    By:
    • Dimopoulos, Meletios A.;
    • Mateos, Maria-Victoria;
    • Richardson, Paul G.;
    • Schlag, Rudolf;
    • Khuageva, Nuriet K.;
    • Shpilberg, Ofer;
    • Kropff, Martin;
    • Spicka, Ivan;
    • Palumbo, Antonio;
    • Wu, Ka Lung;
    • Esseltine, Dixie-Lee;
    • Liu, Kevin;
    • Deraedt, William;
    • Cakana, Andrew;
    • Van De Velde, Helgi;
    • San Miguel, Jesús F.
    Publication type:
    Article
    7

    Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL–TAMO Study Group.

    Published in:
    European Journal of Haematology, 2008, v. 80, n. 3, p. 227, doi. 10.1111/j.1600-0609.2007.01020.x
    By:
    • Arranz, Reyes;
    • Conde, Eulogio;
    • Grande, Carlos;
    • Mateos, Maria Victoria;
    • Gandarillas, Marco;
    • Albo, Carmen;
    • Lahuerta, Juan J.;
    • Fernández-Rañada, José M.;
    • Hernández, Miguel T.;
    • Alonso, Natalia;
    • García Vela, José A.;
    • Garzón, Sebastián;
    • Rodríguez, José;
    • Caballero, Dolores
    Publication type:
    Article
    8

    Medium-term results of percutaneous vertebroplasty in multiple myeloma.

    Published in:
    European Journal of Haematology, 2006, v. 77, n. 1, p. 7, doi. 10.1111/j.0902-4441.2005.t01-1-EJH2355.x
    By:
    • Ramos, Luis;
    • de las Heras, José Antonio;
    • Sánchez, Sergio;
    • González-Porras, José Ramón;
    • González, Rafael;
    • Mateos, Maria Victoria;
    • San Miguel, Jesús F.
    Publication type:
    Article
    9

    Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.

    Published in:
    Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-017-0495-y
    By:
    • López-Iglesias, Ana-Alicia;
    • Herrero, Ana B.;
    • Chesi, Marta;
    • San-Segundo, Laura;
    • González-Méndez, Lorena;
    • Hernández-García, Susana;
    • Misiewicz-Krzeminska, Irena;
    • Quwaider, Dalia;
    • Martín-Sánchez, Montserrat;
    • Primo, Daniel;
    • Paíno, Teresa;
    • Bergsagel, P. Leif;
    • Mehrling, Thomas;
    • González-Díaz, Marcos;
    • San-Miguel, Jesús F.;
    • Mateos, María-Victoria;
    • Gutiérrez, Norma C.;
    • Garayoa, Mercedes;
    • Ocio, Enrique M.
    Publication type:
    Article
    10
    11

    Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.

    Published in:
    Advances in Therapy, 2024, v. 41, n. 2, p. 696, doi. 10.1007/s12325-023-02738-0
    By:
    • Moreau, Philippe;
    • Mateos, María-Victoria;
    • Gonzalez Garcia, Maria Esther;
    • Einsele, Hermann;
    • De Stefano, Valerio;
    • Karlin, Lionel;
    • Lindsey-Hill, Joanne;
    • Besemer, Britta;
    • Vincent, Laure;
    • Kirkpatrick, Suriya;
    • Delforge, Michel;
    • Perrot, Aurore;
    • van de Donk, Niels W. C. J.;
    • Pawlyn, Charlotte;
    • Manier, Salomon;
    • Leleu, Xavier;
    • Martinez-Lopez, Joaquin;
    • Ghilotti, Francesca;
    • Diels, Joris;
    • Morano, Raúl
    Publication type:
    Article
    12
    13
    14

    Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.

    Published in:
    Advances in Therapy, 2020, v. 37, n. 12, p. 4996, doi. 10.1007/s12325-020-01521-9
    By:
    • Hungria, Vania;
    • Martínez-Baños, Deborah M.;
    • Mateos, María-Victoria;
    • Dimopoulos, Meletios A.;
    • Cavo, Michele;
    • Heeg, Bart;
    • Garcia, Andrea;
    • Lam, Annette;
    • Machnicki, Gerardo;
    • He, Jianming;
    • Fernandez, Mariana
    Publication type:
    Article
    15

    Delivery of Health Care by Spanish Dental Hygienists in Private and Public Dental Services during the COVID-19 De-Escalation Phase (June 2020): A Cross-Sectional Study.

    Published in:
    International Journal of Environmental Research & Public Health, 2021, v. 18, n. 16, p. 8298, doi. 10.3390/ijerph18168298
    By:
    • Expósito-Delgado, Antonio Javier;
    • Ausina-Márquez, Verónica;
    • Mateos-Moreno, María Victoria;
    • Martínez-Sanz, Elena;
    • del Carmen Trullols-Casas, María;
    • Llamas-Ortuño, María Eulalia;
    • Blanco-González, José María;
    • Almerich-Torres, Teresa;
    • Bravo, Manuel;
    • Martínez-Beneyto, Yolanda
    Publication type:
    Article
    16

    Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors.

    Published in:
    American Journal of Hematology, 2022, v. 97, n. 7, p. 877, doi. 10.1002/ajh.26566
    By:
    • Gozzetti, Alessandro;
    • Guarnieri, Andrea;
    • Zamagni, Elena;
    • Zakharova, Elena;
    • Coriu, Daniel;
    • Bittrich, Max;
    • Pika, Tomáš;
    • Tovar, Natalia;
    • Schutz, Natalia;
    • Ciofini, Sara;
    • Peña, Camila;
    • Rocchi, Serena;
    • Rassner, Michael;
    • Avivi, Irit;
    • Waszczuk‐Gajda, Anna;
    • Chhabra, Saurabh;
    • Usnarska‐Zubkiewicz, Lidia;
    • González‐Calle, Verónica;
    • Mateos, Maria‐Victoria;
    • Bocchia, Monica
    Publication type:
    Article
    17

    Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.

    Published in:
    American Journal of Hematology, 2022, v. 97, n. 6, p. 700, doi. 10.1002/ajh.26507
    By:
    • Rojas, Elizabeta A.;
    • Corchete, Luis A.;
    • De Ramón, Cristina;
    • Krzeminski, Patryk;
    • Quwaider, Dalia;
    • García‐Sanz, Ramón;
    • Martínez‐López, Joaquín;
    • Oriol, Albert;
    • Rosiñol, Laura;
    • Bladé, Joan;
    • Lahuerta, Juan José;
    • San Miguel, Jesús F.;
    • González, Marcos;
    • Mateos, María Victoria;
    • Bourdon, Jean‐Christophe;
    • Misiewicz‐Krzeminska, Irena;
    • Gutiérrez, Norma C.
    Publication type:
    Article
    18

    Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial.

    Published in:
    American Journal of Hematology, 2022, v. 97, n. 4, p. 481, doi. 10.1002/ajh.26480
    By:
    • Terpos, Evangelos;
    • Dimopoulos, Meletios A.;
    • Boccadoro, Mario;
    • Delimpasi, Sosana;
    • Beksac, Meral;
    • Katodritou, Eirini;
    • Moreau, Philippe;
    • Pompa, Alessandra;
    • Symeonidis, Argiris;
    • Bila, Jelena;
    • Oriol, Albert;
    • Mateos, Maria‐Victoria;
    • Einsele, Hermann;
    • Orfanidis, Ioannis;
    • Gries, Katharine S.;
    • Fastenau, John;
    • Liu, Kevin;
    • He, Jianming;
    • Kampfenkel, Tobias;
    • Qiu, Yanping
    Publication type:
    Article
    19

    Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

    Published in:
    American Journal of Hematology, 2022, v. 97, n. 3, p. E83, doi. 10.1002/ajh.26434
    By:
    • Delimpasi, Sosana;
    • Mateos, Maria Victoria;
    • Auner, Holger W.;
    • Gavriatopoulou, Maria;
    • Dimopoulos, Meletios A.;
    • Quach, Hang;
    • Pylypenko, Halyna;
    • Hájek, Roman;
    • Leleu, Xavier;
    • Dolai, Tuphan Kanti;
    • Sinha, Dinesh Kumar;
    • Venner, Christopher P.;
    • Benjamin, Reuben;
    • Garg, Mamta Krishnan;
    • Doronin, Vadim;
    • Levy, Yair;
    • Moreau, Philippe;
    • Chai, Yi;
    • Arazy, Melina;
    • Shah, Jatin
    Publication type:
    Article
    20
    21

    Authors' Response.

    Published in:
    American Journal of Hematology, 2015, v. 90, n. 8, p. 146, doi. 10.1002/ajh.24079
    By:
    • Mateos, María-Victoria;
    • Shi, Hongliang;
    • San Miguel, Jesús F.
    Publication type:
    Article
    22
    23

    Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.

    Published in:
    American Journal of Hematology, 2014, v. 89, n. 4, p. 355, doi. 10.1002/ajh.23641
    By:
    • Morabito, Fortunato;
    • Bringhen, Sara;
    • Larocca, Alessandra;
    • Wijermans, Pierre;
    • Victoria Mateos, Maria;
    • Gimsing, Peter;
    • Mazzone, Carla;
    • Gottardi, Daniela;
    • Omedè, Paola;
    • Zweegman, Sonja;
    • José Lahuerta, Juan;
    • Zambello, Renato;
    • Musto, Pellegrino;
    • Magarotto, Valeria;
    • Schaafsma, Martijn;
    • Oriol, Albert;
    • Juliusson, Gunnar;
    • Cerrato, Chiara;
    • Catalano, Lucio;
    • Gentile, Massimo
    Publication type:
    Article
    24
    25

    Once‐weekly (70 mg/m<sup>2</sup>) vs twice‐weekly (56 mg/m<sup>2</sup>) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials.

    Published in:
    Cancer Medicine, 2020, v. 9, n. 9, p. 2989, doi. 10.1002/cam4.2945
    By:
    • Moreau, Philippe;
    • Stewart, Keith A.;
    • Dimopoulos, Meletios;
    • Siegel, David;
    • Facon, Thierry;
    • Berenson, James;
    • Raje, Noopur;
    • Berdeja, Jesus G.;
    • Orlowski, Robert Z.;
    • Yang, Hui;
    • Ma, Haijun;
    • Klippel, Zandra;
    • Zahlten‐Kumeli, Anita;
    • Mezzi, Khalid;
    • Iskander, Karim;
    • Mateos, Maria‐Victoria
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32
    33

    Multiple myeloma with t(11;14): impact of novel agents on outcome.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00807-9
    By:
    • Puertas, Borja;
    • González-Calle, Verónica;
    • Sobejano-Fuertes, Eduardo;
    • Escalante, Fernando;
    • Rey-Bua, Beatriz;
    • Padilla, Irene;
    • García-Sanz, Ramón;
    • Puig, Noemi;
    • Gutiérrez, Norma C.;
    • Mateos, María-Victoria
    Publication type:
    Article
    34

    Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00805-x
    By:
    • Moreau, Philippe;
    • Chari, Ajai;
    • Oriol, Albert;
    • Martinez-Lopez, Joaquin;
    • Haenel, Mathias;
    • Touzeau, Cyrille;
    • Ailawadhi, Sikander;
    • Besemer, Britta;
    • de la Rubia Comos, Javier;
    • Encinas, Cristina;
    • Mateos, Maria-Victoria;
    • Salwender, Hans;
    • Rodriguez-Otero, Paula;
    • Hulin, Cyrille;
    • Karlin, Lionel;
    • Sureda Balari, Anna;
    • Bargay, Joan;
    • Benboubker, Lotfi;
    • Rosiñol, Laura;
    • Tarantolo, Stefano
    Publication type:
    Article
    35
    36

    Multiple myeloma with t(11;14): impact of novel agents on outcome.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00807-9
    By:
    • Puertas, Borja;
    • González-Calle, Verónica;
    • Sobejano-Fuertes, Eduardo;
    • Escalante, Fernando;
    • Rey-Bua, Beatriz;
    • Padilla, Irene;
    • García-Sanz, Ramón;
    • Puig, Noemi;
    • Gutiérrez, Norma C.;
    • Mateos, María-Victoria
    Publication type:
    Article
    37

    Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.

    Published in:
    2023
    By:
    • Moreau, Philippe;
    • Chari, Ajai;
    • Oriol, Albert;
    • Martinez-Lopez, Joaquin;
    • Haenel, Mathias;
    • Touzeau, Cyrille;
    • Ailawadhi, Sikander;
    • Besemer, Britta;
    • de la Rubia Comos, Javier;
    • Encinas, Cristina;
    • Mateos, Maria-Victoria;
    • Salwender, Hans;
    • Rodriguez-Otero, Paula;
    • Hulin, Cyrille;
    • Karlin, Lionel;
    • Sureda Balari, Anna;
    • Bargay, Joan;
    • Benboubker, Lotfi;
    • Rosiñol, Laura;
    • Tarantolo, Stefano
    Publication type:
    Letter
    38
    39

    Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 2, p. 1, doi. 10.1038/s41408-022-00629-1
    By:
    • Cohen, Adam D.;
    • Parekh, Samir;
    • Santomasso, Bianca D.;
    • Pérez-Larraya, Jaime Gállego;
    • van de Donk, Niels W. C. J.;
    • Arnulf, Bertrand;
    • Mateos, Maria-Victoria;
    • Lendvai, Nikoletta;
    • Jackson, Carolyn C.;
    • De Braganca, Kevin C.;
    • Schecter, Jordan M.;
    • Marquez, Loreta;
    • Lee, Erin;
    • Cornax, Ingrid;
    • Zudaire, Enrique;
    • Li, Claire;
    • Olyslager, Yunsi;
    • Madduri, Deepu;
    • Varsos, Helen;
    • Pacaud, Lida
    Publication type:
    Article
    40

    Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 2, p. 1, doi. 10.1038/s41408-021-00432-4
    By:
    • Terpos, Evangelos;
    • Mikhael, Joseph;
    • Hajek, Roman;
    • Chari, Ajai;
    • Zweegman, Sonja;
    • Lee, Hans C.;
    • Mateos, María-Victoria;
    • Larocca, Alessandra;
    • Ramasamy, Karthik;
    • Kaiser, Martin;
    • Cook, Gordon;
    • Weisel, Katja C.;
    • Costello, Caitlin L.;
    • Elliott, Jennifer;
    • Palumbo, Antonio;
    • Usmani, Saad Z.
    Publication type:
    Article
    41

    Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 10, p. 1, doi. 10.1038/s41408-020-00372-5
    By:
    • Martínez-López, Joaquín;
    • Mateos, María-Victoria;
    • Encinas, Cristina;
    • Sureda, Anna;
    • Hernández-Rivas, José Ángel;
    • Lopez de la Guía, Ana;
    • Conde, Diego;
    • Krsnik, Isabel;
    • Prieto, Elena;
    • Riaza Grau, Rosalía;
    • Gironella, Mercedes;
    • Blanchard, María Jesús;
    • Caminos, Nerea;
    • Fernández de Larrea, Carlos;
    • Senin, María Alicia;
    • Escalante, Fernando;
    • de la Puerta, José Enrique;
    • Giménez, Eugenio;
    • Martínez-Barranco, Pilar;
    • Mateos, Juan José
    Publication type:
    Article
    42

    Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41408-020-00357-4
    By:
    • Dimopoulos, Meletios A.;
    • Lonial, Sagar;
    • White, Darrell;
    • Moreau, Philippe;
    • Weisel, Katja;
    • San-Miguel, Jesus;
    • Shpilberg, Ofer;
    • Grosicki, Sebastian;
    • Špička, Ivan;
    • Walter-Croneck, Adam;
    • Magen, Hila;
    • Mateos, Maria-Victoria;
    • Belch, Andrew;
    • Reece, Donna;
    • Beksac, Meral;
    • Spencer, Andrew;
    • Oakervee, Heather;
    • Orlowski, Robert Z.;
    • Taniwaki, Masafumi;
    • Röllig, Christoph
    Publication type:
    Article
    43
    44
    45

    Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

    Published in:
    Drugs, 2016, v. 76, n. 9, p. 989, doi. 10.1007/s40265-016-0590-3
    By:
    • Moreau, Philippe;
    • Donk, Niels;
    • Miguel, Jesus;
    • Lokhorst, Henk;
    • Nahi, Hareth;
    • Ben-Yehuda, Dina;
    • Cavo, Michele;
    • Cook, Gordon;
    • Delforge, Michel;
    • Einsele, Hermann;
    • Zweegman, Sonja;
    • Ludwig, Heinz;
    • Driessen, Christoph;
    • Palumbo, Antonio;
    • Facon, Thierry;
    • Plesner, Torben;
    • Dimopoulos, Meletios;
    • Sondergeld, Pia;
    • Sonneveld, Pieter;
    • Mateos, María-Victoria
    Publication type:
    Article
    46

    Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

    Published in:
    Drugs, 2016, v. 76, n. 8, p. 853, doi. 10.1007/s40265-016-0573-4
    By:
    • Moreau, Philippe;
    • Donk, Niels;
    • Miguel, Jesus;
    • Lokhorst, Henk;
    • Nahi, Hareth;
    • Ben-Yehuda, Dina;
    • Cavo, Michele;
    • Cook, Gordon;
    • Delforge, Michel;
    • Einsele, Hermann;
    • Zweegman, Sonja;
    • Ludwig, Heinz;
    • Driessen, Christoph;
    • Palumbo, Antonio;
    • Facon, Thierry;
    • Plesner, Torben;
    • Dimopoulos, Meletios;
    • Sondergeld, Pia;
    • Sonneveld, Pieter;
    • Mateos, María-Victoria
    Publication type:
    Article
    47
    48
    49
    50